We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
126
Arcutis Biotherapeutics
ARQT
$3.34B
$1.64M 0.06%
148,874
– –
RETA
127
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.62M 0.06%
+17,850
New +$1.05M
ETNB
128
DELISTED
89bio
ETNB
$1.61M 0.06%
+105,898
New +$1.38M
XRN
129
Chiron Real Estate Inc
XRN
$462M
$1.59M 0.06%
34,979
– –
GSK icon
130
GSK
GSK
$103B
$1.49M 0.06%
41,852
– –
EWTX icon
131
Edgewise Therapeutics
EWTX
$4.81B
$1.3M 0.05%
195,025
– –
MRUS
132
DELISTED
Merus
MRUS
$1.27M 0.05%
69,025
-23,300
-25% -$406K
CRNX icon
133
Crinetics Pharmaceuticals
CRNX
$8.9B
$1.26M 0.05%
78,529
+32,668
+71% +$605K
ZLAB icon
134
Zai Lab
ZLAB
$2.08B
$1.15M 0.04%
34,640
-8,660
-20% -$332K
GTHX
135
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.14M 0.04%
423,869
– –
MREO
136
Mereo BioPharma
MREO
$50.2M
$1.1M 0.04%
1,551,082
– –
SRRK icon
137
Scholar Rock
SRRK
$5.71B
$871K 0.03%
108,833
– –
ICPT
138
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$699K 0.03%
52,067
– –
MRSN
139
DELISTED
Mersana Therapeutics
MRSN
$667K 0.03%
+6,495
New +$912K
THRX
140
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$666K 0.03%
75,000
-25,000
-25% -$245K
ITOS
141
DELISTED
iTeos Therapeutics
ITOS
$622K 0.02%
+45,735
New +$819K
RCUS icon
142
Arcus Biosciences
RCUS
$3.58B
$599K 0.02%
+32,839
New +$628K
TCMD icon
143
Tactile Systems Technology
TCMD
$672M
$565K 0.02%
+34,432
New +$480K
NBP
144
NovaBridge Biosciences American Depositary Shares
NBP
$192M
$563K 0.02%
162,580
– –
CHCT
145
Community Healthcare Trust
CHCT
$435M
$545K 0.02%
14,900
– –
UHT
146
Universal Health Realty Income Trust
UHT
$582M
$542K 0.02%
11,258
– –
NHI icon
147
National Health Investors
NHI
$3.63B
$518K 0.02%
10,038
– –
BEAM icon
148
Beam Therapeutics
BEAM
$2.76B
$484K 0.02%
15,817
– –
DHC
149
Diversified Healthcare Trust
DHC
$2.23B
$483K 0.02%
357,720
– –
BHVN icon
150
Biohaven
BHVN
$2.06B
$479K 0.02%
35,087
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.